Comment: Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease

Abstract

Get full access to this article

View all access options for this article.

References

Schafer

Casey

Dupre

Staubes

BA.

Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease. Ann Pharmacother. 2019;53:104.

January

Wann

Alpert

et al . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76. doi:10.1161/CIR.0000000000000040

Kearon

Akl

Ornelas

et al . Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149:315-352. doi:10.1016/j.chest.2015.11.026

Lexicomp. Lexi-drugs online. http://online.lexi.com/. Ac-cessed July 18, 2018.

Chokesuwattanaskul

Thongprayoon

Tanawuttiwat

Kaewput

Pachariyanon

Cheungpasitporn

Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis. Pacing Clin Electrophysiol. 2018;41:627-634. doi:10.1111/pace.13331